ArticleEBioMedicine2017
Nasopharyngeal Protein Biomarkers of Acute Respiratory Virus Infection.
Article in EBioMedicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 20 citations in OpenAlex.
- Molecular dynamics of the host response to Streptococcus pneumoniae pneumonia in baboons.Animal models and experimental medicine · 2025Article
- Co-infection in unvaccinated infants with acute pertussis in Western China (2018-2019): pathogen distribution and impact on disease severity.Italian journal of pediatrics · 2025Article
- A Comprehensive Machine Learning Approach for COVID-19 Target Discovery in the Small-Molecule Metabolome.Metabolites · 2025Article
- Application of MALDI-TOF MS and machine learning for the detection of SARS-CoV-2 and non-SARS-CoV-2 respiratory infections.Microbiology spectrum · 2024Article
- Multiplex protein profiling of bronchial aspirates reveals disease-, mortality- and respiratory sequelae-associated signatures in critically ill patients with ARDS secondary to SARS-CoV-2 infection.Frontiers in immunology · 2022Article
- Cytokine expression patterns in hospitalized children with Bordetella pertussis, Rhinovirus or co-infection.Scientific reports · 2021Article
- Precise Investigation of the Efficacy of Multicomponent Drugs Against Pneumonia Infected With Influenza Virus.Frontiers in pharmacology · 2021Article
- Clinical and Virological Characteristics of Acute Sinusitis in Children.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019Article
- A crowdsourced analysis to identify ab initio molecular signatures predictive of susceptibility to viral infection.Nature communications · 2018Article
- The manufacturing of human viral challenge agents for use in clinical studies to accelerate the drug development process.BMC research notes · 2018Review
- Immune responses in influenza A virus and human coronavirus infections: an ongoing battle between the virus and host.Current opinion in virology · 2018Review
- Mass Spectrometry Reveals Respiratory Viral Infection Biomarkers.EBioMedicine · 2017Article
Corrections and comments
- Commented on by
Authors and funding
16 authors at 5 institutions in 2 countries.
Funding
Abstract
Infection of respiratory mucosa with viral pathogens triggers complex immunologic events in the affected host. We sought to characterize this response through proteomic analysis of nasopharyngeal lavage in human subjects experimentally challenged with influenza A/H3N2 or human rhinovirus, and to develop targeted assays measuring peptides involved in this host response allowing classification of acute respiratory virus infection. Unbiased proteomic discovery analysis identified 3285 peptides corresponding to 438 unique proteins, and revealed that infection with H3N2 induces significant alterations in protein expression. These include proteins involved in acute inflammatory response, innate immune response, and the complement cascade. These data provide insights into the nature of the biological response to viral infection of the upper respiratory tract, and the proteins that are dysregulated by viral infection form the basis of signature that accurately classifies the infected state. Verification of this signature using targeted mass spectrometry in independent cohorts of subjects challenged with influenza or rhinovirus demonstrates that it performs with high accuracy (0.8623 AUROC, 75% TPR, 97.46% TNR). With further development as a clinical diagnostic, this signature may have utility in rapid screening for emerging infections, avoidance of inappropriate antibacterial therapy, and more rapid implementation of appropriate therapeutic and public health strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.